Prosecution Insights
Last updated: September 26, 2026
Application No. 18/240,673

SYSTEMS AND METHODS FOR NEUROLOGIC REHABILITATION

Non-Final OA §112§DP
Filed
Aug 31, 2023
Priority
Apr 14, 2016 — provisional 62/322,504 +2 more
Examiner
JANG, CHRISTIAN Y
Art Unit
Tech Center
Assignee
Medrhythms Inc.
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
8m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
587 granted / 857 resolved
+8.5% vs TC avg
Strong +21% interview lift
Without
With
+21.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
46 currently pending
Career history
883
Total Applications
across all art units

Statute-Specific Performance

§101
16.5%
-23.5% vs TC avg
§103
38.7%
-1.3% vs TC avg
§102
13.8%
-26.2% vs TC avg
§112
23.5%
-16.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 857 resolved cases

Office Action

§112 §DP
DETAILED ACTION Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 28, 33, 35, 43, 45, and 46 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 28 is currently dependent on itself. For purposes of examination, it is understood to depend on claim 27. Claims 33 and 44 recites the limitation "a target motion" in line 3. It is unclear whether this is the same target motion found in the independent claims or a separate target motion. Claim 35 recites “a sensor” in line 4. It is unclear whether this is the same sensor of claim 27. Claim 43 is currently dependent on itself. For purposes of examination, it is understood to depend on claim 42. Claim 45 is currently dependent on itself. For purposes of examination, it is understood to depend on claim 44. Claim 46 recites “a sensor associated with the patient”. It is unclear whether this is the same sensor of claim 38 or not. In addition, while claim 38 recites that the biomechanical data is measured using a sensor, claim 46 recites that the computer system is configured to measure the biomechanical data. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 27-47 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-26 of U.S. Patent No. 10,448,888 in view of Montgomery (US 2010/0075806). As to claims 27-47, the ‘888 patent recites similar subject matter with the exception of analyzing the biomechanical data to determine an accuracy of motion for repetitive movement relative to a target motion and modifying the rhythmic audio content as a function of both the entrainment parameter and the accuracy of motion. Montgomery teaches the evaluation of a movement of a user and providing biofeedback by providing a rhythm to the user and modifying it in response to the user’s movement to a reference movement, which would be an assessment of the accuracy of the repetitive movement relative to a target movement ([0063]). Accordingly, it would have been obvious to modify the above patent with Montgomery to also utilize the accuracy of the movement to provide feedback to the user. Claims 27-47 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-25 of U.S. Patent No. 11,779,274 in view of Montgomery (US 2010/0075806). As to claims 27-47, the ‘888 patent recites similar subject matter with the exception of analyzing the biomechanical data to determine an accuracy of motion for repetitive movement relative to a target motion and modifying the rhythmic audio content as a function of both the entrainment parameter and the accuracy of motion. Montgomery teaches the evaluation of a movement of a user and providing biofeedback by providing a rhythm to the user and modifying it in response to the user’s movement to a reference movement, which would be an assessment of the accuracy of the repetitive movement relative to a target movement ([0063]). Accordingly, it would have been obvious to modify the above patent with Montgomery to also utilize the accuracy of the movement to provide feedback to the user. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Cassily (USP #7,122,004) teaches enhancing a user’s learning capacity by generating a guidance signal which is a function between the generation of a reference signal and user’s manipulation of a trigger (col. 4 lines 1-9). Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTIAN JANG whose telephone number is (571)270-3820. The examiner can normally be reached Monday-Friday (7-3:30 EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Chen can be reached at 571-272-3672. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CHRISTIAN JANG Primary Examiner Art Unit 3791 /CHRISTIAN JANG/Primary Examiner, Art Unit 3791 7/30/26
Read full office action

Prosecution Timeline

Aug 31, 2023
Application Filed
Aug 03, 2026
Non-Final Rejection mailed — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12727833
MODEL BASED VARIABLE RISK FALSE GLUCOSE THRESHOLD ALARM PREVENTION MECHANISM
4y 1m to grant Granted Sep 08, 2026
Patent 12725702
METHOD AND SYSTEM FOR PROVIDING BASAL PROFILE MODIFICATION IN ANALYTE MONITORING AND MANAGEMENT SYSTEMS
3y 10m to grant Granted Sep 01, 2026
Patent 12714351
HIGH RESOLUTION ELECTROENCEPHALOGRAPH SIGNAL ACQUISITION SYSTEM
3y 5m to grant Granted Aug 25, 2026
Patent 12708297
CONTINUOUS ELECTROCHEMICAL MONITORING
3y 8m to grant Granted Aug 18, 2026
Patent 12708291
Breathing amplitude detection system, method, and computer program based on micro force detection
2y 8m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
90%
With Interview (+21.0%)
3y 9m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 857 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month